Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Henry Byabajungu"'
Autor:
Beatrice Kemilembe Mutayoba, Michael Hoelscher, Norbert Heinrich, Moses L. Joloba, Eligius Lyamuya, Andrew Martin Kilale, Nyagosya Segere Range, Bernard James Ngowi, Nyanda Elias Ntinginya, Saidi Mwinjuma Mfaume, Amani Wilfred, Basra Doulla, Johnson Lyimo, Riziki Kisonga, Amri Kingalu, Jupiter Marina Kabahita, Ocung Guido, Joel Kabugo, Isa Adam, Moses Luutu, Maria Magdalene Namaganda, Joanitah Namutebi, George William Kasule, Hasfah Nakato, Henry Byabajungu, Pius Lutaaya, Kenneth Musisi, Denis Oola, Gerald Mboowa, Michel Pletschette
Publikováno v:
BMC Genomics, Vol 23, Iss 1, Pp 1-9 (2022)
Abstract Background Mycobacterium tuberculosis presents several lineages each with distinct characteristics of evolutionary status, transmissibility, drug resistance, host interaction, latency, and vaccine efficacy. Whole genome sequencing (WGS) has
Externí odkaz:
https://doaj.org/article/6a1b4021e10a4ae888c4acaae43752f5
Autor:
Jupiter Marina Kabahita, Joel Kabugo, Francis Kakooza, Isa Adam, Ocung Guido, Henry Byabajungu, Joanitah Namutebi, Maria Magdalene Namaganda, Pius Lutaaya, James Otim, Fredrick Elishama Kakembo, Stephen Kanyerezi, Patricia Nabisubi, Ivan Sserwadda, George William Kasule, Hasfah Nakato, Kenneth Musisi, Denis Oola, Moses L. Joloba, Gerald Mboowa
Publikováno v:
Antimicrobial Resistance and Infection Control, Vol 11, Iss 1, Pp 1-8 (2022)
Abstract Background Uganda remains one of the countries with the highest burden of TB/HIV. Drug-resistant TB remains a substantial challenge to TB control globally and requires new strategic effective control approaches. Drug resistance usually devel
Externí odkaz:
https://doaj.org/article/cad884e9023b41ef984fe5713b3076f0
Autor:
Dennis Mujuni, Dianah Linda Kasemire, Ivan Ibanda, Joel Kabugo, Andrew Nsawotebba, Jody E. Phelan, Robert Kaos Majwala, Didas Tugumisirize, Abdunoor Nyombi, Beatrice Orena, Irene Turyahabwe, Henry Byabajungu, Diana Nadunga, Kenneth Musisi, Moses Lutakoome Joloba, Willy Ssengooba
Publikováno v:
BMC Infectious Diseases, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Second-line drug resistance (SLD) among tuberculosis (TB) patients is a serious emerging challenge towards global control of the disease. We characterized SLD-resistance conferring-mutations among TB patients with rifampicin and/o
Externí odkaz:
https://doaj.org/article/b4fe0f0a25e346c2b75f7b87a1e86af9
Autor:
Joel Kabugo, Joanita Namutebi, Isa Adam, Dennis Mujuni, Didas Tugumisirize, Oola Denis, George William Kasule, Ivan Ibanda, Beatrice Orena, Henry Byabajungu, Elizabeth Nampewo, Moses Joloba
Publikováno v:
PLoS ONE, Vol 18, Iss 3, p e0282650 (2023)
BackgroundProficiency testing (PT) has been hard to set up due to cost limitations and technical capacity. Conventional Xpert MTB/RIF PT programs use liquid and culture spots which require stringent storage and transportation conditions with cross-co
Externí odkaz:
https://doaj.org/article/524145659ef9451394023d6e3625019a
Autor:
Willy Ssengooba, Kevin Komakech, Sharon Namiiro, Henry Byabajungu, Joanitah Nalunjogi, Winceslaus Katagira, Ivan Kimuli, Moses L Joloba, Susan Adakun, Lydia Nakiyingi, Gabriela Torrea, Bruce J Kirenga
Publikováno v:
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, Vol 25, Iss , Pp 100286- (2021)
Tuberculosis (TB) resistance to rifampicin, the most powerful drug leads to increase in mortality. Globally, half a million new patients develop such resistant TB each year, coupled with both inappropriate diagnosis and treatment initiation.We report
Externí odkaz:
https://doaj.org/article/2089ea3e49994b73aa467bc594eb9ba4
Autor:
Dennis Mujuni, Willy Ssengooba, Ivan Ibanda, Joel Solomon Kabugo, Dianah Linda Kasemire, Elizabeth Nampewo, Andrew Nsawotebba, Jody E Phelan, Didas Tugumisirize, Beatrice Orena, Henry Byabajungu, Nathan Ntenkaire, Diana Nadunga, Julius Tumwine, Kenneth Musisi, Moses Joloba, Seungmo Kim, Ikwap Kokas, William Olaho Mukani, Joseph Kungu, Mathias Afayoa
Publikováno v:
F1000Research. 12:62
Background Increased tuberculosis disease burden arises as a result of low treatment success rates stemming from the emergence of second-line drug resistance. We aimed at determining the usefulness of second-line drug (SLD) resistance markers as prox
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4adf2fede9e6d475bb39e558e48bfa2
https://doi.org/10.12688/f1000research.129524.1
https://doi.org/10.12688/f1000research.129524.1
Autor:
Dennis Mujuni, Dianah Linda Kasemire, Ivan Ibanda, Joel Kabugo, Andrew Nsawotebba, Jody E. Phelan, Robert Kaos Majwala, Didas Tugumisirize, Abdunoor Nyombi, Beatrice Orena, Irene Turyahabwe, Henry Byabajungu, Diana Nadunga, Kenneth Musisi, Moses Lutakoome Joloba, Willy Ssengooba
Publikováno v:
BMC infectious diseases. 22(1)
Background Second-line drug resistance (SLD) among tuberculosis (TB) patients is a serious emerging challenge towards global control of the disease. We characterized SLD-resistance conferring-mutations among TB patients with rifampicin and/or isoniaz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f800f0e677fc672b7184842a4189ce10
https://pubmed.ncbi.nlm.nih.gov/35410160
https://pubmed.ncbi.nlm.nih.gov/35410160
Autor:
Jupiter Marina Kabahita, Joel Kabugo, Francis Kakooza, Isa Adam, Ocung Guido, Henry Byabajungu, Joanitah Namutebi, Maria Magdalene Namaganda, Pius Lutaaya, James Otim, Fredrick Elishama Kakembo, Stephen Kanyerezi, Patricia Nabisubi, Ivan Sserwadda, George William Kasule, Hasfah Nakato, Kenneth Musisi, Denis Oola, Moses L. Joloba, Gerald Mboowa
Background Uganda remains one of the countries with the highest burden of TB/HIV. Drug-resistant TB remains a substantial challenge to TB control globally and requires new strategic effective control approaches. Drug resistance usually develops due t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::266d488fa6cf93e0d4e7b564da35b878
Autor:
Joseph F Imoko, Emily Bloss, Bruce Kirenga, Terry Lo, Lilian Bulage, Moses Joloba, Henry Byabajungu, Keneth Musisi
Publikováno v:
Journal of Tuberculosis Research. :97-106
Setting: The Uganda National Tuberculosis Reference Laboratory (NTRL) in Kampala. Objective: The proportion of poor quality specimens received for drug susceptibility testing (DST) at the NTRL and factors contributing to poor specimen quality were as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0491b4ae90382df8efcfa5655a7a30d
https://doi.org/10.4236/jtr.2015.33015
https://doi.org/10.4236/jtr.2015.33015